Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.
Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.
Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.
Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.
Enanta Pharmaceuticals reported fiscal Q3 2022 revenue of $19.5 million, primarily from royalties on AbbVie's MAVYRET®, a decline from $21.6 million in Q3 2021. R&D expenses decreased to $39.1 million from $47.0 million, while G&A expenses rose to $12.9 million from $8.5 million. The net loss was $31.7 million ($1.53 per share), compared to $24.0 million ($1.19 per share) in the previous year. Enanta plans to initiate Phase 2 studies for its COVID-19 treatment EDP-235 and RSV treatment EDP-938 in Q4 2022.
Enanta Pharmaceuticals, a clinical-stage biotechnology company, appointed Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer on August 8, 2022. Dr. Rottinghaus brings over 20 years of drug development experience, notably leading clinical programs at Alexion and Pfizer. His expertise will support Enanta's ongoing clinical programs, including a Phase 2 study on COVID-19 and advancements in respiratory syncytial virus (RSV). This appointment aims to further Enanta's goal of becoming a leader in antiviral treatments.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is set to announce its financial results for Q3 2022, concluded on June 30, 2022, on August 8, 2022, post-market. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and updates on the company’s R&D pipeline. Enanta focuses on drug discovery for viral infections and liver diseases, including respiratory syncytial virus (RSV) and hepatitis B virus (HBV), while funding is supported by royalties from its collaboration with AbbVie on hepatitis C virus (HCV) treatments.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced positive topline data from a Phase 1 study of EDP-235, a coronavirus 3CL protease inhibitor. The study showed EDP-235 was generally safe and well-tolerated at doses up to 400mg. Plasma drug levels exceeded the EC90 by up to 12-fold for the Delta variant. Preclinical data indicated significant lung tissue distribution, making it a candidate for once-daily oral treatment against COVID-19 variants. Enanta plans to initiate a Phase 2 study in 4Q 2022, pending FDA review.
Enanta Pharmaceuticals (NASDAQ: ENTA) has filed a lawsuit against Pfizer in the U.S. District Court for the District of Massachusetts, seeking damages for patent infringement concerning U.S. Patent No. 11,358,953, related to Pfizer's COVID-19 antiviral, Paxlovid™. Enanta was awarded this patent based on its July 2020 application. The company emphasizes it won't seek to impede Paxlovid’s availability, instead aiming for compensation for its use of a coronavirus protease inhibitor outlined in its patent.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that data from its hepatitis B virus (HBV) development program and non-alcoholic steatohepatitis (NASH) out-licensing program will be presented at the EASL International Liver Congress 2022 from June 22-26 in London. The presentations will include findings from Phase 1b studies of EDP-514, a core inhibitor for HBV, and results from EDP-297, a Farnesoid X receptor agonist for NASH, as well as data on HSD17B13 enzyme inhibition.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced CEO Jay R. Luly, Ph.D., will participate in two fireside chats in June 2022. The events include the Jefferies Healthcare Conference on June 9 at 9:00 a.m. ET and the JMP Securities Life Sciences Conference on June 16 at 9:30 a.m. ET. Webcast links will be available on Enanta's website, along with replays for 30 days post-event. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with candidates for RSV, COVID-19, and HBV under development.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced topline results from its Phase 2b RSVP study of EDP-938 for RSV treatment, which did not meet its primary endpoint of clinical symptom reduction. However, a statistically significant number of subjects achieved undetectable RSV RNA by Day 5. The study demonstrated EDP-938's safety and tolerability. Enanta plans to continue development in high-risk populations, emphasizing the urgency for effective treatments in these groups. Future studies, including pediatric and high-risk adult populations, are underway.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported $18.7 million in royalty revenue for Q2 2022, a decrease from $20.1 million in Q2 2021. The net loss widened to $33.6 million, or $1.63 per share, compared to a loss of $22.0 million, or $1.09 per share, year-on-year. The company expects topline data from the Phase 2b RSVP study for EDP-938 and preliminary results from the Phase 1 EDP-235 study this quarter, with Fast Track designations granted for both. Enanta’s cash reserves stand at $322.5 million, expected to last for at least two years, supporting ongoing development programs.
Enanta Pharmaceuticals plans to report its financial results for the fiscal second quarter ended March 31, 2022, on May 9, 2022. A conference call will follow at 4:30 p.m. ET to discuss results and updates on the company's research pipeline, which focuses on small molecule drugs for viral infections and liver diseases, including targets like RSV, COVID-19, and HBV. Enanta's R&D is funded by royalties from HCV products developed in collaboration with AbbVie, notably Glecaprevir, part of its leading treatment for chronic HCV infections.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
